Intra-Cellular Therapies

About:

Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS.

Website: http://www.intracellulartherapies.com

Top Investors: Deerfield, Broadfin Capital

Description:

Intra-Cellular Therapies (ITI) develop new drugs for neuropsychiatric, neurologic diseases, and other Central Nervous System (CNS) disorders. The company integrates the work of medicinal scientists, pharmacologists, biologists, and clinical development scientists to create novel treatments. ITI's lead product, ITI-007, is a first-in-class 5-HT2A antagonist and dopamine receptor phosphoprotein modulator designed to treat schizophrenia with fewer side effects compared to current antipsychotic drugs. ITI has also developed CNSProfileTM, a technology platform that generates molecular signatures for drug compounds, providing insights into the intracellular actions of CNS drugs. This tool helps in drug discovery and development and is used to study the effects of brain-damaging nerve agents, leading to collaborations on antidotes for chemical warfare agents. Additionally, ITI is exploring new drug candidates for symptoms related to the transition from peri-menopause to post-menopause.